Kassberg Thomas Richard 4
4 · Ultragenyx Pharmaceutical Inc. · Filed Mar 3, 2023
Insider Transaction Report
Form 4
Kassberg Thomas Richard
CBO & Senior Vice President
Transactions
- Award
Common Stock
2023-03-01+2,663→ 230,222 total - Award
Common Stock
2023-03-01+22,000→ 252,222 total - Sale
Common Stock
2023-03-01$45.27/sh−1,968$89,091→ 250,254 total - Disposition to Issuer
Common Stock
2023-03-01$45.65/sh−3,394$154,936→ 246,860 total - Award
Stock Option (Right to Buy)
2023-03-01+39,400→ 39,400 totalExercise: $45.65Exp: 2033-03-01→ Common Stock (39,400 underlying)
Footnotes (6)
- [F1]Represents shares of common stock which previously granted performance stock units were converted on March 1, 2023 upon certification of the performance metric.
- [F2]Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.
- [F3]Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
- [F4]Shares were acquired upon the partial vesting of a previously reported RSU and were sold to permit the cash value of the awards to be credited to the deferred compensation plan account of the Reporting Person
- [F5]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- [F6]On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.